Introduction {#Sec1}
============

In 2016, the burden of acne vulgaris---a chronic inflammatory skin disease---was estimated to be approximately \$3 billion in healthcare costs and lost productivity in the USA \[[@CR1]\]. This underscores the fact that acne is an important disease, worthy of attention, and not just a simple adolescent complaint. Over the past decade, a number of consensus recommendations and evidence-based guidelines have been created to help guide clinicians in selection of treatments for acne \[[@CR2]--[@CR7]\]. Acne-focused expert groups within the dermatology community, including the American Acne and Rosacea Society and the Global Alliance to Improve Outcomes in Acne, have consistently recommended that most patients with acne be treated with a combination of topical retinoid and antimicrobial therapy \[[@CR2]--[@CR4]\]. The recommendations are based on both clinical trial data from thousands of patients and bench data showing the drug classes have different and complementary mechanisms of action that target multiple aspects of acne's complex pathophysiology \[[@CR2], [@CR3]\]. Recent evidence-based guidelines for acne, including those from the American Academy of Dermatology (AAD) and the European S3 guidelines from the European Dermatology Forum (EDF), have agreed that retinoids have an important role in this widespread disease \[[@CR5], [@CR7]\]. The AAD guidelines state that "retinoids are the core of topical therapy for acne because they are comedolytic, resolve the precursor microcomedone lesion, and are anti-inflammatory;" furthermore, they "allow for maintenance of clearance" \[[@CR7]\].

Yet both our anecdotal experiences from interacting with other physicians and more recent data have confirmed past studies indicating that topical retinoids are under-used for acne \[[@CR1], [@CR8], [@CR9]\]. In a data set from the American insurance company Humana that included 87,970 individuals with acne who consulted dermatologists (*n* = 74,371) or non-dermatologist physicians (*n* = 13,599), dermatologists were almost twice as likely to prescribe a retinoid when compared with non-dermatologists (58.8% vs. 32.4%) \[[@CR1]\]. A high proportion of dermatologists (41.2%) and a significant majority (67.6%) of non-dermatologists did not prescribe retinoids \[[@CR1]\]. Both dermatologists and other physicians were less likely to prescribe a retinoid for patients aged 19 or older compared to those aged 10--19 \[[@CR1]\]. Due to these data, we would like to review the evidence supporting why retinoids should be considered the foundation of acne therapy (with a focus on topical retinoids) and suggest how to overcome some of the perceived barriers to use. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Role of Retinoids in Acne Management {#Sec2}
------------------------------------

It is generally agreed that multiple molecular pathways are involved in acne, with four primary pathophysiologic mechanisms \[[@CR3], [@CR10], [@CR11]\]:Abnormal desquamation within the sebaceous follicles that leads to obstruction of the pilosebaceous canal.Androgen-driven excess sebum production.Proliferation within the follicle by *Propionibacterium acnes*, which generates proinflammatory stimuli.Altered immune system activity and inflammation.

While there is an interplay among the pathogenic factors, abnormal desquamation and sebaceous hyperplasia are arguably the most important because together they are thought to induce the microcomedone---the precursor of all acne lesions \[[@CR11]--[@CR13]\]. The essential action of inflammation in all ongoing processes of acne---from the initiation of the microcomedone to the secondary lesions (typically long-lasting sequelae such as scars and pigmentation that are very bothersome for the patient)---is also increasingly appreciated \[[@CR12], [@CR14]--[@CR17]\].

Topical retinoids (adapalene 0.1% and 0.3%; tazarotene 0.1%; tretinoin 0.01%, 0.025%, 0.038%, 0.04%, 0.05%, 0.08%, and 0.1% in the USA; isotretinoin 0.05% and 0.1% in other regions of the world) have a central role in acne therapy because they have been shown both to reduce visible lesions and also inhibit the development of microcomedones and new lesions \[[@CR12], [@CR18]\]. Retinoids act to normalize desquamation by reducing keratinocyte proliferation and promoting differentiation \[[@CR19]\]. Topical retinoids also block several important inflammatory pathways that are activated in acne: Toll-like receptors, leukocyte migration, and the AP-1 pathway \[[@CR19], [@CR20]\]. In the case of adapalene, these molecular actions have been shown to be dose dependent (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR21]\]. However, it is clear that isotretinoin, tretinoin, and tazarotene also suppress Toll-like receptor expression. Blocking these pathways reduces the release of inflammatory cytokines and nitric oxide and inhibits cellular inflammation \[[@CR2], [@CR19], [@CR22], [@CR23]\].Fig. 1Dose-dependent actions of adapalene at the molecular level. From Tenaud et al. \[[@CR21]\]

### Dose-Dependent Effects on Primary Acne Lesions {#Sec3}

The efficacy of individual topical retinoids increases with increasing concentration. Tretinoin was first shown to have dose-dependent effects in animal models \[[@CR24]\]. In two separate ultra-structural studies, 12 weeks of tretinoin therapy (0.1% and 0.025%) reduced microcomedones by 80% and 35%, respectively \[[@CR18], [@CR25]\]. Registration studies of adapalene gel 0.3% consistently showed superior dose-related efficacy with adapalene 0.3% vs. 0.1% across all efficacy measures, with good tolerability at both dosages \[[@CR26], [@CR27]\]. Analysis of the phase III study of adapalene gel 0.3% showed that the greatest efficacy was achieved in patients who had higher lesion counts at baseline \[[@CR26]\].

Most recently, the fixed combination adapalene 0.3%-benzoyl peroxide (BPO) 2.5% (0.3 A/BPO; Epiduo Forte^®^, Galderma Laboratories) has shown efficacy in a patient population with substantially more severe acne than is typically treated by topical monotherapy \[[@CR28]\]. The higher concentration 0.3 A/BPO was associated with higher clinical success rates and efficacy on all types of acne lesions (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR28]\].Fig. 2Dose-dependent clinical success rate (IGA) of 0.3 A/BPO, A/BPO, and vehicle in patients with severe acne at baseline. From Weiss et al. \[[@CR68]\]

### Effects on Secondary Acne Lesions {#Sec4}

In addition to affecting primary acne lesions, topical retinoids have also been shown to act on secondary lesions including scarring and pigmentation because of actions in the dermis. Acne scarring occurs as a result of dermal remodeling and an imbalance between matrix degradation and matrix synthesis that is orchestrated by matrix metalloproteinases (MMPs) \[[@CR29]\]. An open-label pilot study of adapalene 0.3% in subjects with acne scarring showed improvement of one or two grades on a scar assessment scale by week 24, along with better overall skin texture \[[@CR30]\]. Further, adapalene 0.3% was associated with upregulation of procollagen genes and increases in procollagen-1 staining plus collagen-3 staining \[[@CR30]\].

In pigmentary problems, topical retinoids lighten hyperpigmented lesions by inhibiting melanosome transfer to keratinocytes and reducing epidermal pigmentation by accelerating epidermal turnover \[[@CR31]\]. Grimes et al. reported tazarotene 0.1% cream was effective for acne-related PIH, significantly reducing pigmentation intensity and area over 18 weeks compared with vehicle (*P* ≤ 0.05) \[[@CR32]\]. In a study comparing tazarotene 0.1% cream versus adapalene 0.3% gel, Tanghetti et al. reported that 16 weeks of tazarotene significantly decreased PIH in acne patients; adapalene reduced PIH but did not achieve significant differences from baseline \[[@CR33]\]. In addition, 25% (10/40) of the tazarotene-treated subjects had complete resolution of PIH \[[@CR33]\]. Griffiths et al. found that tretinoin 0.1% cream improved pigmentation in melasma patients, with an effect that was significantly superior to vehicle (*P* = 0.0006) \[[@CR34]\]. In an open-label study of South African acne patients with dark skin types, adapalene gel 0.1% reduced both the number of pigmented macules and the density of hyperpigmentation to a degree "comparable to that observed for topical tretinoin," according to the author \[[@CR35]\]. In a 40-week study, Bulengo-Ransby et al. found that facial post-inflammatory hyperpigmented lesions of tretinoin-treated subjects were significantly lighter than those of vehicle-treated subjects (*P* \< 0.001) \[[@CR36]\].

Perceived Barriers to Use of Retinoids {#Sec5}
--------------------------------------

### Efficacy in Inflammatory Acne {#Sec6}

There is a common perception that retinoids should be reserved primarily for comedonal acne \[[@CR37]\]. Randomized controlled trials have provided strong evidence that topical retinoids as monotherapy significantly reduce inflammatory lesions, with an effect that is comparable to that on noninflammatory lesions (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR38]--[@CR40]\]. The beneficial effect of topical retinoids on inflammatory lesions is clear in before and after digital photos of patients undergoing topical retinoid monotherapy \[[@CR37]\]. To evaluate the effect of topical retinoids on inflammatory lesions, Leyden et al. reviewed high-resolution digital photographs from 577 patients treated with topical retinoids in registration studies \[[@CR37]\]. Five blinded investigators rated acne severity before and after 12--15 weeks of monotherapy with topical retinoids (adapalene, tazarotene, or tretinoin). Significant clinical improvement in inflammatory acne was found for all retinoids; in addition, the degree of improvement increased along with worsening baseline acne severity \[[@CR37]\]. In a recent systematic review, Jacobs et al. reported that BPO and adapalene both have fast onset of action (defined as time to 25% reduction in mean inflammatory lesion counts) compared with other retinoids (tretinoin, topical isotretinoin) \[[@CR41]\].Fig. 3Clinical efficacy of topical retinoid monotherapy on inflammatory lesions after 12 or 15 weeks therapy. From Leyden et al. \[[@CR37]\]

### Tolerability {#Sec7}

Topical retinoid therapy can be accompanied by cutaneous irritation, including peeling, erythema, irritation, or dryness, which typically are observed in the first few weeks of treatment and then subside \[[@CR42]\]. Clinically, retinoid-induced irritation is superficial, mild to moderate in severity, and limited to the epidermis \[[@CR43], [@CR44]\]. During the process of normalizing desquamation, corneocyte arrangement can be disturbed with loss of cohesion \[[@CR45]--[@CR47]\]. After a few weeks of treatment, the corneocytes are re-arranged, desquamation normalizes, and irritation resolves \[[@CR45]\]. In clinical trials of retinoids, the peak of cutaneous irritation typically occurs within the first 1--2 weeks and subsides thereafter \[[@CR48]\]. The effect of retinoids on antiinflammatory pathways and on the microcomedo then becomes prominent (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR13], [@CR18], [@CR49], [@CR50]\].Fig. 4Changes over time in the skin with retinoid therapy, differentiating transient irritation versus inflammation. *MoA* mechanism of action, *IL* interleukin, *TNF* tumor necrosis factor

Retinoids have different receptor binding affinities to their target nuclear hormone receptors (retinoic acid receptors or retinoid X receptors) and cellular retinoic acid binding protein II (CRABP II) \[[@CR12]\], and this variance is believed to account for differences in tolerability \[[@CR7], [@CR12]\]. A systematic review of 34 clinical studies (split-face comparisons and parallel designs) showed that the frequency of clinically significant irritation was low with all three available topical retinoids (adapalene, tazarotene, tretinoin) \[[@CR42]\]. Among studies with statistically significant results, adapalene gel 0.1% was the most tolerable retinoid followed by adapalene gel 0.3%. Tazarotene cream 0.1% and tretinoin 0.025% had comparable tolerability. Of note, the review authors reported that sensitive skin (history of irritation with facial products) was the most reliable predictor of irritation---superseding the effect of the specific retinoid, concentration, or formulation \[[@CR42]\]. Leyden et al. evaluated the facial tolerability of topical retinoids in 253 healthy volunteers in randomized, split-face, investigator-blind studies that took place at one study center with the same investigator \[[@CR51]\]. The analysis assessed the influence of four variables on retinoid tolerability: concentration, vehicle formulation, skin sensitivity, and the specific retinoid. The results indicated that vehicle (gel vs. cream) had an impact on tolerability, but whether gel or cream was best tolerated varied by individual retinoid. Generally, tolerability was better with normal vs. sensitive skin and with lower vs. higher retinoid concentrations. On both normal and sensitive skin, the best tolerated cream was tazarotene and the best tolerated gel was adapalene. The results from this study agreed with the systematic review that the sensitivity of the facial skin has at least as much influence on tolerability as the choice of individual retinoid and more than the formulation or concentration \[[@CR51]\].

The systematic review also assessed irritation with a fixed-dose combination product versus retinoid monotherapy and concluded that the tolerability of combinations was comparable to monotherapy \[[@CR42]\]. Three of the studies included for evaluation allowed the use of moisturizers, and Culp et al. said that moisturizers "may have a larger role in retinoid tolerability than intrinsic factors such as concentration and vehicle" \[[@CR42]\]. They emphasize that few patients discontinued clinical trials because of irritation and stress the importance of strategies to minimize irritation \[[@CR42]\].

In our clinical experience, there are a number of strategies that can help minimize the potential for irritation and patients with sensitive skin (Table [1](#Tab1){ref-type="table"}) \[[@CR52], [@CR53]\]. Some of these, such as patient education, may require additional staff time but may also reward the practice via improved patient satisfaction with therapeutic outcomes \[[@CR54]\].Table 1Strategies to minimize tolerability issues \[[@CR7], [@CR53], [@CR69]\]Take a detailed patient history Past tolerability problems?Educate patient Mild irritation can be part of the treatment process, but usually subsides within 1--2 weeks and can be managed with appropriate steps How to apply the retinoid in a thin layer (fingertip or pea-sized dose) Gentle cleansing regimen and avoiding over-cleansingSelect most tolerable retinoid formulation for climate and seasonTitrate retinoid dose at initiation Apply retinoid every other day for first 2--4 weeks (based on clinical trial evidence that this is when irritation is most likely to occur) Apply a gentle, non-comedogenic moisturizer Use a short contact method for the first 2--4 weeks (apply retinoid to full face for 30--60 min then wash off)

It is important to encourage patients to optimize their skin care regimens, and patients can benefit from receiving recommendations for appropriate gentle cleansing and moisturizing products \[[@CR53], [@CR54]\]. Good skin care can prepare the stratum corneum for topical therapies in several ways: reducing skin irritation and improving hydration as well as maintaining a correct pH balance \[[@CR53]\]. Generally, antibacterial soaps are not recommended for acne; these agents do not impact *P. acnes* in the follicle and can allow development of gram-negative folliculitis by selective pressure on gram-positive bacteria \[[@CR53]\]. Synthetic detergent (syndet) bars and lipid-free cleansers are a better choice, cleansing the skin without a negative impact on epidermal barrier function \[[@CR53]\]. Cleansing may be a very important area to address with the patient, since a substantial proportion of people (including medical students) erroneously attribute acne to poor skin hygiene or being dirty \[[@CR55], [@CR56]\].

Predicting which patients will be susceptible to retinoid irritation poses a clinical challenge \[[@CR57]\]. A 2014 study designed to evaluate predictors of irritation with tretinoin cream (*n* = 324) reported 61% of subjects had local adverse effects. Increased risk for side effects was associated with the use of other topical medications (OR 1.88, 95% CI 1.15--3.08) \[[@CR57]\]. Thus, when utilizing topical tretinoin as part of a combination regimen---as is recommended for most patients with acne---it may be prudent to utilize one or more of the strategies listed in Table [1](#Tab1){ref-type="table"}.

### Necessity of Treatment Directed Toward *P. acnes* {#Sec8}

Although *P. acnes* is thought to have a role in acne pathogenesis, that role remains unclear. Acne is not a traditional infectious disease, and approaches targeted solely to killing *P. acnes* do not usually eradicate acne \[[@CR3]\]. Today, benzoyl peroxide (BPO) is the recommended topical antimicrobial choice because it limits the potential for microbial resistance---a key factor in today's era of antimicrobial stewardship \[[@CR58], [@CR59]\]. Topical BPO and antibiotics act by reducing *P. acnes* concentrations and suppressing inflammation \[[@CR2]\]; however, BPO has potent oxidative activity that achieves a 90% reduction in *P. acnes* in 7 days, and no bacterial resistance against BPO has been shown to date \[[@CR2], [@CR60], [@CR61]\]. In addition, BPO has some comedolytic properties, which occur secondary to reduction of free fatty acids \[[@CR60]\]. Topical antibiotics are not recommended as monotherapy, but can be used in combination with BPO \[[@CR7]\]. Combination therapy with topical retinoids and antimicrobials targets three major areas of acne pathophysiology: abnormal desquamation, *P. acnes* proliferation, and inflammation \[[@CR2]\].

Optimizing Acne Therapy {#Sec9}
-----------------------

From both the patient's and the clinician's viewpoint, the two major goals of acne therapy are: (1) to achieve clearance or almost complete clearance of acne lesions and (2) to minimize the potential for long-lasting acne-related sequelae such as scarring, PIH, and erythema \[[@CR53]\]. Optimally, clearance should be sustained by a therapy that can prevent the majority of new lesion formation \[[@CR53]\]. A US study demonstrated that 43% of patients with active acne consulting a dermatologist have scars. As might be intuitive to clinicians, the likelihood of scarring increased with acne severity: 51% of moderate acne patients had scars, and 77% of severe acne patients had scars at the time of the acne consultation \[[@CR62]\]. Acne often follows a chronic relapsing and remitting course, and it is important to have topical medications that decrease the formation of new lesions by targeting the microcomedo, the precursor of acne lesions \[[@CR54], [@CR63]\].

There are a variety of topical retinoid concentrations and formulations currently available, allowing clinicians to design individualized treatment regimens based on the patient's presentation, preferences, and ability to tolerate treatment \[[@CR12]\]. Retinoids are also available in fixed-combination formulations with BPO \[adapalene-BPO 0.1%/2.5% and 0.3%/2.5% (Epiduo^®^ and Epiduo Forte^®^, Galderma Laboratories)\] and clindamycin \[tretinoin 0.025%/clindamycin phosphate 1.2% (Veltin, Aqua Pharmaceuticals; Ziana^®^, Valeant Pharmaceuticals)\] \[[@CR7]\]. The use of retinoids plus BPO targets multiple pathways and can often eliminate the need for antibiotics, reducing the likelihood of antimicrobial resistance \[[@CR2], [@CR3]\]. Dosage may be increased to improve efficacy, since a dose-dependent relationship has been shown for retinoids. Fixed-dose combination formulations can help to streamline therapy, which may be expected to positively impact adherence.

### Synergistic and Additive Effects of Single-Agent Treatment {#Sec10}

Synergistic effects have been reported with the fixed combination of A/BPO, in both modulation of inflammatory markers and clinical efficacy \[[@CR64], [@CR65]\]. Synergy is a term for when the actions of a combination prove to be greater than what might be expected from the sum of the efficacy of the constituents \[[@CR66]\]. In a study of normal skin explants and biopsies from acne papules, Zuliani et al. \[[@CR64]\] reported A/BPO exerted a cooperative effect on markers of keratinocyte proliferation/differentiation (Ki67, transglutaminase, and α2 and α6 integrins) and aspects of innate immunity including decreasing interleukin 8 (IL-8) and interleukin 10 (IL-10). Finally, A/BPO had a synergistic effect in reducing ß4 defensin \[[@CR64]\]. Synergy was also shown in the clinic. Tan et al. analyzed results from large-scale clinical trials involving 3855 patients and found the clinical efficacy of A/BPO is greater than would be expected with a purely additive effect \[[@CR65]\]. The efficacy of the fixed-dose combination product was significantly greater than its constituent molecules and exceeded the sum of the efficacy of adapalene alone plus BPO alone \[[@CR65]\]. To our knowledge, no similar analyses have been performed on the other combination products currently available for the treatment of acne.

In addition, Osman-Ponchet et al. recently reported fixed-combination gels of A/BPO achieve optimal skin absorption that is also markedly increased at the higher A/BPO dose (0.3%) compared with the lower A/BPO dose (0.1%) \[[@CR67]\]. Skin penetration with 0.3% A/BPO was greater than seven times higher than that observed with 0.1% A/BPO \[[@CR67]\]. These results support clinical efficacy findings.

Conclusions {#Sec11}
===========

The scientific rationale for use of topical retinoids in acne is clear \[[@CR2], [@CR3], [@CR37]\]. Clinical data from many thousands of patients show these agents are highly efficacious on both noninflammatory and inflammatory acne lesions \[[@CR3]\]. Expert groups and evidence-based guidelines agree that topical retinoids should be considered the foundation of acne therapy. It is our hope that educational efforts can be made for all clinicians treating acne so that patients receive optimal therapy according to today's best practices.
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